Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760004 | 0.86 | FFAR4 (0.43) | FFAR4FGFR1FGFR4FGFR3FGFR2 | |
| SCHEMBL11920963 | 0.83 | FFAR4 (0.35) | FFAR4FGFR1FGFR4FGFR3FGFR2 | |
| SCHEMBL23008877 | 0.83 | FFAR4 (0.39) | FFAR4FGFR1FGFR4FGFR3FGFR2 | |
| SCHEMBL17713182 | 0.83 | FFAR4 (0.39) | FFAR4FGFR1FGFR4FGFR3FGFR2 | |
| SCHEMBL20074624 | 0.82 | OPRM1 (0.34) | FGFR1FGFR4FGFR3FGFR2OPRM1 | |
| SCHEMBL11920960 | 0.78 | FFAR4 (0.39) | FFAR4FGFR1FGFR4FGFR3FGFR2 | |
| SCHEMBL20073971 | 0.78 | MAP3K12 (0.39) | FFAR4OPRM1HDAC6MAP3K12 | |
| SCHEMBL20073981 | 0.76 | HSD11B1 (0.45) | OPRM1OPRL1OPRD1OPRK1HSD11B1 | |
| SCHEMBL20066130 | 0.75 | FFAR4 (0.38) | FFAR4OPRM1HDAC6 | |
| SCHEMBL23799231 | 0.72 | CYP2D6 (0.41) | FFAR4FGFR1FGFR4FGFR3FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| US-11014880-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-20200290963-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-10759751-B2 | Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20190202783-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-10259787-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | FFAR4 169/4885FGFR1 1515/4885FGFR4 1274/4885 |
| US-20190202783-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | FFAR4 87/4885FGFR1 1792/4885FGFR4 1536/4885 |
| US-20200290963-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | FFAR4 87/4885FGFR1 1792/4885FGFR4 1536/4885 |
| US-11014880-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | FFAR4 87/4885FGFR1 1792/4885FGFR4 1536/4885 |
| US-10259787-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | FFAR4 87/4885FGFR1 1792/4885FGFR4 1536/4885 |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | FFAR4 87/4885FGFR1 1792/4885FGFR4 1536/4885 |
| US-10759751-B2 | Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | FFAR4 130/4885FGFR1 1433/4885FGFR4 1488/4885 |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | FFAR4 87/4885FGFR1 1792/4885FGFR4 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.